Zheng Quan Shi Bao Wang·2025-08-25 00:08Core Insights - The company reported a revenue of 286.04 billion RMB for the first half of 2025, representing a year-on-year decline of 2.95% [1] - Net profit attributable to shareholders was 3.47 billion RMB, down 6.43% year-on-year, with earnings per share at 1.11 RMB [1] Business Segments - The pharmaceutical distribution segment remained stable, accounting for 73.62% of total revenue [1] - The medical device distribution revenue decreased, making up 19.22% of total revenue [1] - The pharmaceutical retail segment achieved growth against the trend, contributing 5.78% to total revenue [1] Cost Management - The company demonstrated effective cost control, with sales, management, and financial expense ratios all declining, optimizing by a total of 0.2 percentage points, which supported profit stability [1]